StockData
Neurocrine Biosciences Inc logo

Neurocrine Biosciences Inc (NBIX) stock

NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/307% below fair value
$165.31−2.09 (-1.25%)

Close on Nov 16, 2026Market cap $16.80BP/E 24.2Yield –

Neurocrine Biosciences total assets

Total assets on the balance sheet at the end of each period.

Neurocrine Biosciences's total assets was $5.36B at Jun 30, 2026. For fiscal 2025 it was $4.63B, up 24.5% from the year before. Over ten years it grew 25.6% a year on average. The highest annual figure on record is $4.63B in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$4.63B+24.5%
FY2024Dec 31, 2024$3.72B+14.4%
FY2023Dec 31, 2023$3.25B+37.3%
FY2022Dec 31, 2022$2.37B+14.3%
FY2021Dec 31, 2021$2.07B+19.5%
FY2020Dec 31, 2020$1.73B+32.8%
FY2019Dec 31, 2019$1.31B+31.5%
FY2018Dec 31, 2018$993.15M+21.5%
FY2017Dec 31, 2017$817.59M+123.9%
FY2016Dec 31, 2016$365.09M-23.1%
FY2015Dec 31, 2015$474.79M+95.4%
FY2014Dec 31, 2014$243.03M+57.1%
FY2013Dec 31, 2013$154.68M-21.1%
FY2012Dec 31, 2012$195.98M+41.6%
FY2011Dec 31, 2011$138.37M-4.2%
FY2010Dec 31, 2010$144.42M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$5.36B+37.8%
Q1 FY2026Mar 31, 2026$4.91B+33.0%
Q4 FY2025Dec 31, 2025$4.63B+24.5%
Q3 FY2025Sep 30, 2025$4.27B+20.7%
Q2 FY2025Jun 30, 2025$3.89B+17.7%
Q1 FY2025Mar 31, 2025$3.69B+6.2%
Q4 FY2024Dec 31, 2024$3.72B+14.4%
Q3 FY2024Sep 30, 2024$3.54B+24.1%
Q2 FY2024Jun 30, 2024$3.31B+26.5%
Q1 FY2024Mar 31, 2024$3.47B+47.1%
Q4 FY2023Dec 31, 2023$3.25B+37.3%
Q3 FY2023Sep 30, 2023$2.85B+32.9%
Q2 FY2023Jun 30, 2023$2.61B+30.3%
Q1 FY2023Mar 31, 2023$2.36B+10.0%
Q4 FY2022Dec 31, 2022$2.37B+14.3%
Q3 FY2022Sep 30, 2022$2.14B+6.3%
Q2 FY2022Jun 30, 2022$2.01B+2.5%
Q1 FY2022Mar 31, 2022$2.14B+16.1%
Q4 FY2021Dec 31, 2021$2.07B+19.5%
Q3 FY2021Sep 30, 2021$2.02B+34.3%
Q2 FY2021Jun 30, 2021$1.96B+29.1%
Q1 FY2021Mar 31, 2021$1.85B+35.6%
Q4 FY2020Dec 31, 2020$1.73B+32.8%
Q3 FY2020Sep 30, 2020$1.50B+27.3%
Q2 FY2020Jun 30, 2020$1.52B+42.1%
Q1 FY2020Mar 31, 2020$1.36B+42.2%
Q4 FY2019Dec 31, 2019$1.31B+31.5%
Q3 FY2019Sep 30, 2019$1.18B+26.4%
Q2 FY2019Jun 30, 2019$1.07B+26.8%
Q1 FY2019Mar 31, 2019$957.72M+18.8%
Q4 FY2018Dec 31, 2018$993.15M+21.5%
Q3 FY2018Sep 30, 2018$933.75M+20.9%
Q2 FY2018Jun 30, 2018$841.32M+11.6%
Q1 FY2018Mar 31, 2018$806.36M+178.7%
Q4 FY2017Dec 31, 2017$817.59M+123.9%
Q3 FY2017Sep 30, 2017$772.50M+93.5%
Q2 FY2017Jun 30, 2017$754.09M–
Q1 FY2017Mar 31, 2017$289.36M–
Q4 FY2016Dec 31, 2016$365.09M–
Q3 FY2016Sep 30, 2016$399.16M–

More Neurocrine Biosciences figures

See a number that looks wrong?